April 25, 2026
View Full PaperHeart Failure With Preserved Ejection Fraction
Key Result
This JACC Scientific Statement provides an updated examination of the epidemiology, pathophysiology, diagnosis, and treatment of heart failure with preserved ejection fraction.
Key Points
- The aim is to explore heart failure with preserved ejection fraction, focusing on its epidemiology, pathophysiology, diagnosis, and treatment options.
- In-depth examination based on recent studies and data
- Focus on pathophysiological-based phenotyping
- Review of pharmacologic and lifestyle interventions
- Incidence and prevalence of HFpEF are increasing due to aging and lifestyle factors.
- Effective pharmacologic and lifestyle treatments can improve clinical status and reduce morbidity and mortality.
- Under-recognition in everyday practice of HFpEF highlights the need for enhanced diagnostic approaches.
Structured PICO
P
Population
Patients with heart failure with preserved ejection fraction (HFpEF)
This JACC Scientific Statement provides an updated examination of the epidemiology, pathophysiology, diagnosis, and treatment of HFpEF, emphasizing the importance of pathophysiological-based phenotyping.
Abstract
The incidence and prevalence of heart failure with preserved ejection fraction (HFpEF) continue to rise in tandem with the increasing age and burdens of obesity, sedentariness, and cardiometabolic disorders. Despite recent advances in the understanding of its pathophysiological effects on the heart, lungs, and extracardiac tissues, and introduction of new, easily implemented approaches to diagnosis, HFpEF remains under-recognized in everyday practice. This under-recognition presents an even greater concern given the recent identification of highly effective pharmacologic-based and lifestyle-based treatments that can improve clinical status and reduce morbidity and mortality. HFpEF is a heterogenous syndrome and recent studies have suggested an important role for careful, pathophysiological-based phenotyping to improve patient characterization and to better individualize treatment. In this JACC Scientific Statement, we provide an in-depth and updated examination of the epidemiology, pathophysiology, diagnosis, and treatment of HFpEF.